V2030_Banner_1280x200


VISION2030: A Forecast for the Field

VISION2030 gathers business-founding scientists and CEOs for in-depth interviews on a decade past and decade ahead. Where we are now, obstacles to overcome, and what is next: for our field, businesses, careers. This gathering comes at a pivotal moment in regenerative medicine and stem cell science, as discovery, translation, and investment intersect. This digital meeting will take place 7-8 January, 2021.

Program Organizers

 

Hans Clevers Square
Hans C. Clevers
ISSCR Past President, Hubrecht Institute, Netherlands
Srivastava-Deepak
Deepak Srivastava
ISSCR Immediate Past PresidentGladstone Institutes/UCSF, USA
Melton photo 3 (1)
Douglas A. Melton
ISSCR Past President, Harvard University, USA
Leonard Zon Headshot
Leonard I. Zon
ISSCR Founder, Boston Children’s Hospital, USA, ISSCR Founder
Christine Mummery Headshot
Christine L. Mummery
ISSCR President, Leiden University Medical Center, Netherlands

 


Thursday, 7 January (12:00 - 17:30 EST)

Welcome Remarks

Christine Mummery, ISSCR President, Leiden University Medical Center, Netherlands
Deepak Srivastava, ISSCR Immediate Past President, Gladstone Institute/UCSF, USA 
Leonard I. Zon, ISSCR Founder, Boston Children’s Hospital, USA

BlueRock Therapeutics Executive Interview 

Emile Nuwaysir Square
Emile Nuwaysir, President and Chief Executive Officer, BlueRock Therapeutics, USA 
Lorenz Studer Square
Lorenz Studer, Founding Scientist, BlueRock Therapeutics l Sloan Kettering Institute for Cancer Research, USA 
Viviane Tabar Square
Viviane Tabar, Founding Scientist, BlueRock Therapeutics l Memorial Sloan Kettering Center, USA 
Arnold Kriegstein Square
Interviewed by ISSCR Board Member Arnold Kriegstein, University of California, San Francisco, USA  

BlueRock Therapeutics is advancing their novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology. 

Surrozen Executive Interview 

Craig Parker Square
Craig Parker, Chief Executive Officer, Surrozen, USA
Claudia Janda Square
Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder
Hans Clevers Square
Interviewed by ISSCR Past President Hans C. Clevers, Hubrecht Institute, Netherlands l Surrozen 
Surrozen is pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and restore organs damaged by serious disease. 

ElevateBio Executive Interview 

Mitchell Finer Square
Mitchell Finer, Scientific Founder and President, ElevateBio, USA 
Melissa Carpenter Square
Melissa Carpenter, Chief Scientific Officer, ElevateBio, USA  
Martin Pera Square
Interviewed by ISSCR Board Member Martin Pera, The Jackson Laboratories, USA l Stem Cell Reports Editor-in-Chief 

ElevateBio is accelerating the rate of innovation in cell and gene therapy with a disruptive capital-efficient model. 

STEMCELL Technologies Executive Interview

 
Allen Eaves Square
Allen Eaves, Scientific Founder l Chief Executive Officer, STEMCELL Technologies, Canada 
Valentina Greco Square
Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA  

STEMCELL Technologies' mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools and services that enable life science research. 

Vertex Pharmaceuticals Executive Interview 

Jeffrey Leiden Square
Jeffrey Leiden, Executive Chairman, Vertex Pharmaceutical, USA 
Bastiano Sanna Square
Bastiano Sanna, Executive Vice President, Chief of Cell & Genetic Therapies & VCGT Site Head, Vertex Pharmaceuticals, USA
Melton photo 3 (1)
Interviewed by ISSCR Past President Douglas A. Melton, Scientific Founder, Semma Therapeutics, now Vertex Pharmaceutical l Harvard University, USA  

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. 

Futurecast—STEMCELL Technologies

(Sponsored Content)

Andrew Gaffney Square
Andrew Gaffney, Associate Director, iPSC and Differentiated Cells

Tenaya Therapeutics Executive Interview 

Faraz Ali Square
Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, USA 
Srivastava-Deepak
Deepak Srivastava, Scientific Founder, Tenaya Therapeutics l Gladstone Institute/UCSF, USA l ISSCR Immediate Past President 
Chuck Murry Square
Interviewed by ISSCR Board Member Charles E. Murry, Institute for Stem Cell and Regenerative Medicine, University of Washington/Sana Biotechnologies, USA  

Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease. 

Fate Therapeutics Executive Interview 

Scott Wolchko Square
Scott Wolchko, President and Chief Executive Officer, Fate Therapeutics, USA 
Leonard Zon Square
Leonard I. Zon, Scientific Founder, Fate Therapeutics l Boston Children’s Hospital, USA l ISSCR Founder 
Takebe_Takanori
Interviewed by ISSCR Board Member Takanori Takebe, Cincinnati Children's Hospital Medical Center, USA/Tokyo Medical and Dental University and Yokohama City University, Japan  

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.  

Thought Leaders—Pivoting to the Future

Srivastava-Deepak
Panelists interviewed by Deepak Srivastava
ISSCR Immediate Past President/President, Gladstone Institutes, USA
Margaret Hamburg Square
Margaret A. Hamburg, Co-Chair, WHO Expert Advisory Group On Developing Global Standards for Governance and Oversight of Human Genome Editing and Global Standards for Governance and Oversight of Human Genome Editing l Former FDA Commissioner, USA
Rajev Kaul Square
Rajiv Kaul, Sector Manager, Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund, USA
Andy Plump Square
Andrew Plump, President, Research & Development, Takeda Pharmaceutical Company Limited and Member of the Board of Directors, USA
Jim Tananbaum Square
Jim Tananbaum, Founder and Chief Executive Officer, Foresite Capital, USA

Concluding Remarks 

Christine Mummery, ISSCR President, Leiden University Medical Center, Netherlands 

Friday, 8 January (12:00 - 13:30 EST)

Sponsored Industry Career Talks 

Join us as participating companies discuss how the future of our field will shape the future of our careers – new opportunities, paths, and challenges. Attendees will hear from HR Leaders and scientists, discussing the transition from academia to industry, how to make it, and what to expect.   

Welcome

Keith Alm
Keith Alm, Chief Operating Officer, International Society for Stem Cell Research (ISSCR), USA
Julia Tischler Square
Julia Tischler, ISSCR Membership Committee l Research Scientist in Stem Cell Biology and Bioengineering, École Polytechnique Fédérale de Lausanne, Switzerland

STEMCELL Technologies

Christine Genge Square
Christine Genge, Manager, Recruitment
Nina Quiskamp Square
Nina Quiskamp, Scientist

Audience Question and Answer

BlueRock Therapeutics

Timsi Rao Square
Timsi Rao, Scientist III, Genome Sciences, BlueRock Therapeutics
Stephany Sakharny Square
Stephany Sakharny, Senior Human Resources Manager, BlueRock Therapeutics

Audience Question and Answer

ElevateBio

Cherylene Plewa Square
Cherylene Plewa, PhD, VP, Cellular Engineering, ElevateBio
Austin Thiel Square
Austin Thiel, PhD, Director Stem Cell Biology, ElevateBio

Audience Question and Answer

STEMCELL Technologies400x200
Gold Sponsor
BlueRock400x200
Silver Sponsor
ElevateBio_400x200
Silver Sponsor
Agilent400x200
Bronze Sponsor
BioLamina400x200
Bronze Sponsor
Catalent400x200
Bronze Sponsor
Third Rock_400x200
Bronze Sponsor

 

Companies interested in sponsoring an ISSCR Digital program, can reach out to ISSCR Industry Relations at exhibits@isscr.org.